Health Discovery Corporation’s Dr. Stephen Barnhill Tells Participants at London Conference That Biomarkers Patented by His Company Promise to Revolutionize The Field of Molecular Diagnostics

SAVANNAH, Ga. -- (BUSINESS WIRE) -- Dr. Stephen Barnhill, Chairman and CEO, Health Discovery Corporation (OTCBB: HDVY) (“HDC”), a molecular diagnostics company, spoke at the “Biomarkers in Clinical Trials” Conference taking place in London, September 23-24, 2009. The conference is sponsored by The SMi Group, a London-based business-to-business conference group.

“Biomarkers promise to sharply accelerate the speed and accuracy of the drug discovery process and the efficacy of diagnostic testing,” said Dr. Barnhill. “Genetic biomarkers are at the heart of the new prostate cancer tests we have licensed to Quest Diagnostics and Abbott Laboratories. Combined with our sophisticated analysis tools for identifying positive results from massive amounts of previously unusable clinical data, biomarkers like those patented by HDC promise to revolutionize the field of molecular diagnostics.”

HDC has licensed rights to develop a new urine-based test for clinically significant prostate cancer to Quest Diagnostics Incorporated (NYSE: DGX). HDC has also entered into an agreement with Abbott Laboratories (NYSE: ABT) to commercialize HDC’s new molecular diagnostics gene-based tests for clinically significant prostate cancer.

Dr. Barnhill was joined on the conference faculty by representatives of Pfizer, Novartis Institutes for BioMedical Research, Astrazeneca, Merck Serono, MD Anderson Cancer Center and GlaxoSmithKline, among others.

About Health Discovery Corporation

Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding future performance, opportunities and investments, and anticipated results in general. From time to time the Company may make other forward-looking statements relating to other matters, including without limitation, commercialization plans and strategic partnerships. Actual results may differ materially due to a variety of factors, including, among other things, the acceptance of our approach to applying mathematics computer science and physics into the disciplines of biology, organic chemistry and medicine and our products and technologies associated with those approaches, the ability to develop or commercialize new drugs, therapies or other products based on our approaches, and other factors set forth from time to time in the Company’s Securities and Exchange Commission filings.

All forward-looking statements and cautionary statements included in this document are made as of the date hereof based on information available to the Company as of the date hereof, and the Company assumes no obligation to update any forward-looking statement or cautionary statement.